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The in vivo administration of monoclonal antibody to products of the I-A
subregion of the immune response gene complex (I region), within the major
histocompatibility complex (H-2), has been successful in the prevention of exper-
imental allergic encephalomyelitis (EAE) and experimental autoimmune myas-
thenia gravis (EAMG) (1, 2). To establish the clinical relevance of this novel
therapy for autoimmune disease, we have investigated the effects of such treat-
ment in acute and chronic relapsing EAE by instituting treatment at the onset
of paralytic signs and then following the clinical course .
EAE serves as a model for demyelinating disease of the central nervous system,
and is frequently used to test potential therapies for demyelinating disease . The
disease follows T cell sensitization to myelin basic protein (3), and susceptibility
to EAE is in part a dominant trait strongly linked to the genes of the major
histocompatibility complex (MHC) (4) . Recently, a chronic form ofEAE hasbeen
established in mice (5, 6) . Such a disease is chronic, with relapsing and remitting
features resembling multiple sclerosis (MS) clinically and histologically .
Materials and Methods
Animals
SJL/J mice 8-10-wk old, were purchased from The Jackson Laboratory (Bar Harbor,
ME) .
Monoclonal Antibodies
Monoclonal antibody from hybridoma 10.3 .6 recognizes a public specificity (Ia.17)
found on I-A' cells and is an IgG2A (1) . BP 107 recognizes I-Ab,d .9 .u ; and is an IgGI (2) .
The binding titers of the hybridomas were >10' on the appropriate spleen cells . Ascites
fluid preparations of the antibody were used in all experiments .
Ininaunizations
For Induction (f Relapsing EAE.
￿
Mice were immunized at three sites on the back on
days 0, 7, and 21 with 1 mg of syngeneic mouse spinal cord homogenate (MSCH) in 300
ul of 50% phosphate-buffered saline (PBS) and 50% of incomplete Freund's adjuvant to
which was added 30 wg of H37RA (Difco Laboratories Inc ., Detroit, MI) . Mice were
examined daily and weighed on alternate days throughout the course of the disease .
Therapy rendered was randomized according to the designated cage numbers . For
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example, in Experiment 1 all animals in odd numbered cages received monoclonal anti-
I-As 200 Al (containing 0.6 mg IgG; N. Adelman and H. O. McDevitt, personal commu-
nication, reference 7) i.p. weekly (Group I) throughout the period of observation,
beginning from the first clinical sign of disease. Control animals (Group II) received no
treatment. In Experiments 2 and 3 control animals (Group II) received an irrelevant
monoclonal, BP107 anti-I-Ad, 200 tal i.p. weekly. A clinical relapse was defined as an
unequivocal new paralysis of a limb or tail, recurrent paralysis of a previously paralyzed
limb or tail, or the development of ataxia (inability to right in the absence ofappendicular
weakness). Weight loss and incontinence without any of the above findings was . not
recorded as a relapse. At the onset ofthe first clinical paralytic sign, and weekly thereafter,
animals were bled by tail vein for serial antibody measurements. Animals were sacrificed
on day 130 and the brain and spinal cord were obtained for histopathology.
Induction of Acute EAE.
￿
5 mg of mouse spinal cord homogenate in 0.1 ml complete
Freund's adjuvant containing 400 Ag of H37RA mycobacteria was injected into the hind
foot pads. Immediately after each immunization and 48 h later, Bordetella pertussis (30
x 10 organism in 0.5 ml PBS) was injected via tail vein. Animals were weighed daily and
observed every 8 h from day 10. At the first sign of clinical disease (which was on day 12)
animals were divided into two groups. All animals in cages 1-3, received 0.5 ml of an
ascitic fluid (containing 1 .5 mg IgG) preparation of monoclonal antibody 10.3.6 (anti-1-
As) intraperitoneally daily. This was continued until day 20 . Animals in cages 4-6, received
intraperitoneal injections of a similar volume of PBS for the same duration. In a follow-
up, control animals were treated with an irrelevant anti-I-Ad monoclonal antibody
(BPI 07), with results similar to those of PBS treatment. Animals were weighed daily and
changes in clinical status were observed and recorded. Gradation of disease was scored
according to the clinical status as follows: 0, no evidence of clinical disease; 1, paralysis of
tail with no paralysis of lower extremities; 2, paralysis of tail with weakness ofone or more
lower extremities; 3, complete paralysis of lower extremities; 4, moribund; *, mice died
during acute attack. Animals were sacrificed on day 27 and histology of brain and cervical
spinal cord was evaluated as described previously (1).
Measurement ofAntibody to Myelin Basic Protein
A microtiter ELISA assay was adopted to measure the antibody titer to MBP. Briefly,
to titrate anti-MBP antibody, 2 .5 jig of bovine basic protein (an amount in antigen excess)
diluted in 50 Al phosphate buffer (pH 6.0) was coated on to Falcon polystyrene plates
(Oxnard, CA) and incubated for 2 h. The plates were rinsed with wash solution containing
0.9% NaCl and 0.05% Tween. The wells were then serially incubated for 1 h with 0.2%
bovine serum albumin (BSA), mouse anti-MBP serum (dilution 1 :250, 1 :500, or 1 :2,000
in PO,-Tween solution) and 1 % horse serum in PBS, with rinsing in between incubation.
Similar results were obtained at all three dilutions. Control wells were incubated with
normal mouse serum (diluted either 1 :250, 1 :500, or 1 :2,000). Beta galactosidase conju-
gated sheep anti-mouse antibody (Fab)2 (Bethesda Research Laboratories, Gaithersburg,
MD) diluted 1 :200 in PO,-Tween buffer was then added and incubated again for 1 h.
The plates were rinsed and the substrate, p-nitrophenyl B-D-galactopyranoside was added.
The degree of substrate catalysis was determined from absorbance at 405 nM using an
automated spectrophotometer.
Results
To determine whether anti I-AS antibody would alter the progression of
chronic EAE in SJL mice (H-25), we followed the clinical course of anti-I-As
antibody treated and untreated animals for 4 1/2 mo. Table I describes features
of the clinical course of the disease in two groups of animals. Treatment was
begun at the earliest onset of clinical signs: group I (the treatment group) received
monoclonal anti-I-AS antibody weekly while group II (the control) received
either a non-cross-reactive monoclonal antibody (BP 107, anti I-Ad) (9 animals)
or no treatment at all (14 animals). Five animals (21 %) died during the acute
attack in group' II, while there was no mortality in the anti-I-As treated group.1364
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TABLE I
Clinical Features ofAnti-1-A Antibody Treatment in Chronic Relapsing
EAE
* P < 0.04.
$P < 0.08.
§ One mouse had a third relapse.
P < 0.001 .
Five initial relapses were observed in the treated group (Group 1), while of the
surviving animals in the control (Group II) 12 mice had an initial relapse, X
2 =
4.007 (P < 0.04). At day 130 there was a cumulative total of 18 relapses in
group II, while in group I only 7 relapses were seen, X2 = 13.1 (P < 0.001).
Therewas no mortality (0/18) in the I-As treated group, while mice that received
anti-I-Ad antibody or no treatment had a 30% (7/23) mortality, X2 = 4.34 (P <
0.04). Animals that received such long-term therapy showed no obvious delete-
rious effects.
Weekly measurement of antibody to myelin basic protein (MBP) showed a
decrease in antibody levels in animals that received anti-I-As antibody (Fig. 1).
This reduction in levels occurred 5 wk after the start of treatment and continued
throughout the period of observation. In individual animals the level of antibody
did not correlate clearly with changes in the clinical state. When the animal was
bled in temporal proximity to a clinical relapse, there was no consistent change
in antibody levels compared with the previous weeks.
Histopathology of brain showed qualitative differences between control and
treated groups. Animals that received anti-I-ASantibody had fewerparenchymal
infiltrates and a lesser degree of demyelination (S. DeArmond, S. Sriram, and
L. Steinman, manuscript in preparation).
In order to test the efficacy of anti-I-A antibody in acute EAE, monoclonal
anti-I-AS antibody was administered during the first signs ofacute clinical disease.
Beginning on day 11, mice were observed every 8 h. While most animals
developed tail weakness as the first sign, six animals displayed hind limb paralysis
and three animals became moribund after appearing normal 8 h earlier. Treat-
ment with anti-I-As antibody produced striking clinical improvement. With the
exception of two animals that were already moribund at the start of anti-I-AS
antibody therapy, all other animals that received anti-I-AS antibody showed no
features of clinical progression (Fig. 2). Animals in clinical stages II and III
showed a dramatic improvement within 24-48 h, and by 72 h they all appeared
clinically well. After 1 wk of such therapy, and then observation for one more
week, no mice relapsed or developed disease de novo. Mice that did not receive
Initial attack Number of
mice
Date of onset (d)
(mean ± SD) Mortality
Group I 18 32 ± 9 0/18
Group II 23 32 ± 12 5/23
First relapse
Group 1 5/18* 78 ± 14$ 0/5
Group II 12/18* 61 ± 20$ 2/12
Second relapse
Group 1 2/18 105 ± 12 0/2
Group 11 5/16§ 99 t 16 0/5
Cumulative totals Number of relapses Mortality at day 130
Group I 71 0/18*
Group II 18, 7/23*0.5
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WEEKS AFTER FIRST PARALYTIC SIGN
FIGURE 1 . Antibody levels to MBP in animals with chronic relapsing EAE after onset of
paralytic signs. Left panel shows antibody levels to MBP in animals that received weekly
injections of anti-I-Asantibody. Right panel shows levels in control animals. (Serum dilution
1:250).
the appropriate monoclonal antibody, getting either PBS or the irrelevant
monoclonal antibody anti-I-Ad, showed the characteristic features ofacute EAE.
The degree ofseverity ofthe paralysis increased on days 13 and 14 with gradual
recovery by the end of 1 wk. At the time of termination of the experiment, all
eight animals in the treated group were clinically normal. In contrast, in the
control group, of the surviving eight animals three were grade 11, two were
grade 1, and three were clinically normal. Weight changes paralleled closely the
clinical status of the animals (data not shown). Routine histopathology of the
brain and cervical spinal cord showed the presence ofinflammatory cells in both
treated and untreated groups. Using standard histological criteria (1), no differ-
ence was observed between the two groups.
Discussion
These experiments extend earlier observations on the efficacy ofin vivo anti-
I-A antibody therapy in autoimmune disease (1, 2, 7). The mechanism ofaction
of anti-I-A antibody to IR gene products in the treatment of acute and chronic
EAE remains speculative. Since suppression ofdisease occurs after an established
T cell response, it is unlikely, though possible, that suppression works by blocking
macrophage presentation ofthe encephalitogenic determinant to T cells. Admin-
istration of anti-I-A antibody also has been shown to induce suppressor cells in
vivo (8). Such a mechanism could be involved in explaining the action ofanti-1-
AS in chronic EAE.
Although Tcells are sufficient to transfer EAE to susceptible animals, the role
ofB cells in the demyelinative process is less certain. B cells are observed in the
inflammatory cuffand oligoclonal bands appear in the CSF ofanimals with EAE
(9, 10). Also, prevention of B cell differentiation in suckling rats leads to a1366
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FIGURE 2 .
￿
Suppression of acute EAE with monoclonal antibody to immune response gene
product. Right-hand panel represents the clinical course of animals that received monoclonal
anti I-As antibody; left-hand panel shows clinical course in control animals. Gradation ofclinical
disease explained in text.
decrease in the severity ofacute EAE (11). Since sensitization to MBP is sufficient
to cause relapsing EAE (12), the observed reduction in anti-MBP titers may
explain in part the therapeutic effects of anti-I-A treatment.
The cause of the dramatic and rapid reversal of the clinical course in acute
EAE merits other considerations. Anti-I-A antibody could block the effector
function of I-A-positive cells at the inflammatory site. Macrophages, B and T
cells are seen in the perivascular cuff and are shown to be involved in experi-
mental demyelination (9, 13) and multiple sclerosis (14). Thus, although lympho-
cytes and monocytes are observed in perivascular cuffs in mice that had received
anti-I-AS antibody, it is possible that the effector functions of these cells were
impaired. Furthermore, endothelial cells are known to express I-A antigens (15)
and may play a role in local cell-mediated immunity.
Several of the known human autoimmune diseases and MS are linked to the
IR genes (HLA-D) (16) in man. It is quite likely that the autoantigens that cause
EAE are not analogous to those causing human demyelinating disease such as
MS. However, both the experimental autoimmune model and multiple sclerosis
might share a final common pathway where the putative "antigen(s)" that trigger
the pathologic process, are recognized through a common immune response
gene product. Suppression of the allelic product associated with disease suscep-
tibility offers a novel means of immunological therapy (7). Such an approach
could be tested in man when the appropriate antibodies become available.
Summary
To test the clinical relevance of monoclonal anti-I-A antibody in autoimmune
disease, we investigated the effects of such a therapy in acute and chronic
relapsing experimental allergic encephalomyelitis (EAE) by instituting treatment
after the onset of paralytic signs and following the clinical course. In chronicSRIRAM AND STEINMAN
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relapsing EAE, animals treated with anti-1-A' antibody had no mortality and
fewer relapses when compared with control animals. Antibody levels to myelin
basic protein were lower and histopathology showed milder lesions in the treated
group. Similarly, in the acute EAE model, animals treated with anti-I-AS antibody
showed a dramatic reversal of paralytic signs and a rapid recovery. The mecha-
nisms of action of antibody to IR gene products in autoimmune disease are
discussed.
The excellent technical assistance of Mae Lim, Manu Brahmam, and Teri Montgomery,
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